Objective: This investigation delineates the pharmacokinetic intricacies encountered in the therapeutic management of a geriatric patient with Parkinson’s Disease (PD) concomitantly suffering from refractory Major Depressive Disorder (MDD), with a specific focus on the drug interaction between paroxetine and ziprasidone.
Background: The case study probes into the treatment of a geriatric patient with PD, further complicated by refractory MDD. The initial regimen of ziprasidone for PD-related apathy yielded modest improvements. However, the addition of paroxetine presents a paradigmatic example of the complexities inherent in neuropsychiatric comorbidity management within PD, spotlighting the quintessential pharmacokinetic challenges, viz a viz-risks.
Method: An analysis was conducted on the pharmacokinetic entanglement precipitated by the integration of paroxetine into the existing ziprasidone regimen by the neurologic care team. This study emphasizes the emergent QTc interval prolongation and explores its ramifications within the ambit of PD and MDD co-management.
Results: Subsequent to paroxetine incorporation, a rapid, pronounced QTc interval prolongation (>550 ms) was observed. While a direct causative link to the cardiac anomaly remains speculative, the temporal association with the pharmacotherapeutic adjustment suggests a potential elevation in ziprasidone plasma levels, potentially mediated by paroxetine-induced CYP2D6 enzymatic inhibition.
Conclusion: This underscores the imperative for meticulous, informed pharmacological decision-making in the realm of geriatric neurology, especially amidst psychiatric comorbidities. It emphasizes the critical need for physicians to possess acute awareness of complex pharmacokinetic interactions, championing the ethos of interdisciplinary collaboration to preempt adverse drug interactions. This discourse significantly enriches the conversation on refining neuropharmacological approaches, with a paramount focus on patient safety and optimizing treatment outcomes in the delicate nature of geriatric patient care.
To cite this abstract in AMA style:
D. Nolasco, L. Schmidt, B. Carr. Pharmacokinetic Intersections in Geriatric Neuropharmacology: A Parkinson’s Disease Case Study with Concomitant Refractory Major Depressive Disorder [abstract]. Mov Disord. 2024; 39 (suppl 1). https://www.mdsabstracts.org/abstract/pharmacokinetic-intersections-in-geriatric-neuropharmacology-a-parkinsons-disease-case-study-with-concomitant-refractory-major-depressive-disorder/. Accessed October 5, 2024.« Back to 2024 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/pharmacokinetic-intersections-in-geriatric-neuropharmacology-a-parkinsons-disease-case-study-with-concomitant-refractory-major-depressive-disorder/